PRNewsWire
01 Jun 2026, 02:37 UTC · 4h ago
Source · https://www.prnewswire.com/news-releases/asco-2026--oricells-gpc3-car-t-ori-c101-hits-66-7-orr-in-late-line-hcc-signaling-best-in-class-potential-302786638.html
Read source
Search tags
Story key points
4 claims · impact-rated
Oricell's Ori-C101 achieved a 66.7% objective response rate (ORR) in late-line refractory hepatocellular carcinoma patients. — This is a massive improvement over the historical ORR of below 13% for this patient population, signaling high clinical efficacy and potential for market leadership.
+0.80The Ori-C101 data from the registrational Phase Ib BEACON study has been selected for an oral presentation at the ASCO 2026 Annual Meeting. — Oral presentations at ASCO are high-visibility events that typically act as catalysts for biotech stock valuation and partnership interest.
+0.50Oricell's Ori®OnGo platform has reduced ex vivo culture time to 3 days and vein-to-vein time to within 15 days. — Significant reductions in manufacturing time and COGS improve the commercial scalability and accessibility of CAR-T therapies, which are traditionally slow and expensive.
+0.40Continue reading
6 related stories
The company's AI-powered Ori®Ab platform has compressed the antibody discovery and screening cycle from 12 months to 3 months. — Faster R&D cycles reduce the time-to-market for new candidates and increase the company's overall pipeline efficiency.
+0.30Ticker attribution
Model heads
The company reported highly positive clinical results for its lead CAR-T asset, achieving a 66.7% objective response rate in late-line HCC.
No ticker relationship head found.
Impact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
7h ago
